| 0 (0%) | 01-19 18:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 145.4  |
1-year : | 169.83 |
| Resists | First : | 124.48 |
Second : | 145.4 |
| Pivot price | 99.23 |
|||
| Supports | First : | 92.66 |
Second : | 73 |
| MAs | MA(5) : | 120.37 |
MA(20) : | 94.26 |
| MA(100) : | 64.24 |
MA(250) : | 48.89 |
|
| MACD | MACD : | 12.4 |
Signal : | 9.1 |
| %K %D | K(14,3) : | 95.8  |
D(3) : | 96 |
| RSI | RSI(14): 83.1 |
|||
| 52-week | High : | 124.48 | Low : | 29.17 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RVMD ] has closed below upper band by 22.3%. Bollinger Bands are 454% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 124.56 - 125.2 | 125.2 - 125.69 |
| Low: | 118.15 - 118.81 | 118.81 - 119.31 |
| Close: | 119.25 - 120.34 | 120.34 - 121.18 |
Sun, 18 Jan 2026
Is Revolution Medicines (RVMD) Share Price Justified After Strong Multi Year Rally? - simplywall.st
Fri, 16 Jan 2026
Reassessing Revolution Medicines (RVMD) Valuation After FDA Breakthrough Therapy Designation For Zoldonrasib - simplywall.st
Fri, 16 Jan 2026
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Fri, 16 Jan 2026
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - MSN
Wed, 14 Jan 2026
Revolution Medicines (RVMD) Price Target Increased by 10.10% to 92.82 - Nasdaq
Fri, 09 Jan 2026
Merck in Talks to Buy Revolution Medicines Per Financial Times Report - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 193 (M) |
| Shares Float | 174 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 102.3 (%) |
| Shares Short | 15,070 (K) |
| Shares Short P.Month | 17,490 (K) |
| EPS | -5.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.56 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -762 (M) |
| Levered Free Cash Flow | -438 (M) |
| PE Ratio | -23.18 |
| PEG Ratio | 0 |
| Price to Book value | 14.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -30.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|